2. Search Result
Search Result
Results for "

Ki67

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

3

Inhibitory Antibodies

2

Natural
Products

2

Recombinant Proteins

7

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0169A
    Methyl aminolevulinate hydrochloride
    1 Publications Verification

    		 Reactive Oxygen Species (ROS) Photosensitizer Cancer
    Methyl aminolevulinate hydrochloride is a sensitizer used in photodynamic therapy (PDT). Methyl aminolevulinate hydrochloride penetrates the skin and induces the production of photoactive porphyrins including protoporphyrin IX in cells; upon exposure to appropriate light, it generates ROS, which triggers cellular oxidation and cell death. Methyl aminolevulinate hydrochloride acts as a photo-damage reversing agent through epidermal reconstruction, cytokine-mediated activation of dermal fibroblasts, elastin breakdown, new collagen formation, and compression of dilated capillaries. Methyl aminolevulinate hydrochloride reduces the expression of the proliferation marker Ki-67 and the early skin carcinogenesis marker TP53. Methyl aminolevulinate hydrochloride delays the onset of ultraviolet-induced skin tumors and reduces tumor burden in hairless mice. Methyl aminolevulinate hydrochloride is applicable to research related to actinic keratosis and basal cell carcinoma .
    Methyl aminolevulinate hydrochloride
  • HY-B1941
    4-tert-Octylphenol
    2 Publications Verification

    		 Endogenous Metabolite Apoptosis DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    4-tert-Octylphenol, a endocrine-disrupting chemical, is an estrogenic agent. 4-tert-Octylphenol is also a biodegradation product of non-ionic surfactants alkylphenol polyethoxylates. 4-tert-Octylphenol induces apoptosis in neuronal progenitor cells in offspring mouse brain. 4-tert-Octylphenol reduces bromodeoxyuridine (BrdU), mitotic marker Ki67, and phospho-histone H3 (p-Histone-H3), resulting in a reduction of neuronal progenitor proliferation. 4-tert-Octylphenol disrupts brain development and behavior in mice, which is promising for reserch of immune response, neuro-related diseases and ethology .
    4-tert-Octylphenol
  • HY-150082
    CP681301

    		CDK DNA/RNA Synthesis Cancer
    CP681301 is a potent CDK5 inhibitor. CP681301 shows antiproliferative activity. CP681301 decreases the expression of CD133, OLIG2, SOX2, KI67, pCDK5 protein level in GSCs (Glioma stem cells). CP681301 reduces self-renewal in mouse glioma xenografts. CP681301 shows anti-tumor activity in Drosophila .
    CP681301
  • HY-B1035
    Levobunolol hydrochloride
    1 Publications Verification

    l-Bunolol hydrochloride

    		 Adrenergic Receptor Calcium Channel Casein Kinase Cardiovascular Disease
    Levobunolol (l-Bunolol) hydrochloride is a non-selective β-adrenergic antagonist and vasodilator. By blocking calcium ion influx and reducing the sensitivity of vascular smooth muscle to calcium, Levobunolol hydrochloride effectively dilates the ciliary arteries and increases ocular blood flow, so it is widely used in research on glaucoma and ocular hypertension. Levobunolol hydrochloride inhibits the β-receptor signaling pathway and the expression of related proliferation markers (such as CK3, CK14, CK19, Ki67) in corneal cells. In rabbit models, Levobunolol hydrochloride not only does not inhibit corneal epithelial regeneration, but also accelerates the healing of mechanical injury without adverse effects. Levobunolol hydrochloride also inhibits histamine-induced vasoconstriction and intracellular calcium elevation, exhibiting unique vascular regulatory activity. Levobunolol hydrochloride protects ocular blood flow and promotes corneal repair .
    Levobunolol hydrochloride
  • HY-156096
    HDAC3-IN-2

    		HDAC Histone Methyltransferase Caspase Apoptosis DNA/RNA Synthesis Cancer
    HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .
    HDAC3-IN-2
  • HY-119715
    AG-012986

    		CDK Apoptosis Inflammation/Immunology Cancer
    AG-012986 is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
    AG-012986
  • HY-169265
    BRD-K20733377

    		Bcl-2 Family Others
    BRD-K20733377 is an inhibitor for Bcl-2, and exhibits selective cytotoxicity against senescent cells, that inhibits the viability of Etoposide (HY-13629)-induced IMR-90 senescent cell with an IC50 of 10.7 μM. BRD-K20733377 reduces the mRNA expression of aging-related genes p16, p21 and KI67 in aged mouse model .
    BRD-K20733377
  • HY-162382
    KTC1101

    		PI3K Akt mTOR Cancer
    KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response .
    KTC1101
  • HY-P991664
    AG01

    		Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR Cancer
    AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .
    AG01
  • HY-P11153
    HGH fragment 176-191

    		Estrogen Receptor/ERR Cancer
    HGH fragment 176-191 is a fragment of Human Growth Hormone. HGH fragment 176-191 binds with high affinity to Ki-67, MiB protein, and the estrogen receptor. HGH fragment 176-191 enhances the toxicity of Doxorubicin (HY-15142A)-loaded Chitosan nanoparticles against breast cancer .
    HGH fragment 176-191
  • HY-155244
    12R-LOX-IN-2

    		Lipoxygenase DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .
    12R-LOX-IN-2
  • HY-183208
    Ki-67 peptide/BSA

    		Biochemical Assay Reagents Others
    Ki-67 peptide/BSA is an antigen-adjuvant conjugate conjugate of Ki-67 peptide and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.
    Ki-67 peptide/BSA
  • HY-156872
    MTX-216

    		PI3K EGFR Syk Apoptosis Cancer
    MTX-216 is a dual ATP-competitive inhibitor of PI3K and EGFR. MTX-216 cosuppresses Ki-67 and ribosomal S6 phosphorylation and induces apoptosis in NF1 LOF cells. MTX-216 suppresses the activity of SYK kinase, with an IC50 of 281 nM. MTX-216 is used in the research of Melanoma .
    MTX-216
  • HY-155243
    12R-LOX-IN-1

    		DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC50: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .
    12R-LOX-IN-1
  • HY-P991408
    DLX-105

    		TNF Receptor Interleukin Related IFNAR Inflammation/Immunology
    DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
    DLX-105
  • HY-P991419
    MSB-0254

    		VEGFR Cancer
    MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
    MSB-0254
  • HY-B1941R
    4-tert-Octylphenol (Standard)

    		Reference Standards Endogenous Metabolite Apoptosis DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    4-tert-Octylphenol (Standard) is the analytical standard of 4-tert-Octylphenol. This product is intended for research and analytical applications. 4-tert-Octylphenol, a endocrine-disrupting chemical, is an estrogenic agent. 4-tert-Octylphenol is also a biodegradation product of non-ionic surfactants alkylphenol polyethoxylates. 4-tert-Octylphenol induces apoptosis in neuronal progenitor cells in offspring mouse brain. 4-tert-Octylphenol reduces bromodeoxyuridine (BrdU), mitotic marker Ki67, and phospho-histone H3 (p-Histone-H3), resulting in a reduction of neuronal progenitor proliferation. 4-tert-Octylphenol disrupts brain development and behavior in mice, which is promising for reserch of immune response, neuro-related diseases and ethology .
    4-tert-Octylphenol (Standard)
  • HY-156077
    anti-TNBC agent-2

    		Apoptosis DNA/RNA Synthesis Cancer
    anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .
    anti-TNBC agent-2
  • HY-A0169
    Methyl aminolevulinate

    		Reactive Oxygen Species (ROS) Photosensitizer Cancer
    Methyl aminolevulinate is a sensitizer used in photodynamic therapy (PDT). Methyl aminolevulinate penetrates the skin and induces the production of photoactive porphyrins including protoporphyrin IX in cells; upon exposure to appropriate light, it generates ROS, which triggers cellular oxidation and cell death. Methyl aminolevulinate acts as a photo-damage reversing agent through epidermal reconstruction, cytokine-mediated activation of dermal fibroblasts, elastin breakdown, new collagen formation, and compression of dilated capillaries. Methyl aminolevulinate reduces the expression of the proliferation marker Ki-67 and the early skin carcinogenesis marker TP53. Methyl aminolevulinate delays the onset of ultraviolet-induced skin tumors and reduces tumor burden in hairless mice. Methyl aminolevulinate is applicable to research related to actinic keratosis and basal cell carcinoma .
    Methyl aminolevulinate
  • HY-B1035A
    Levobunolol

    l-Bunolol

    		 Adrenergic Receptor Casein Kinase Calcium Channel Others
    Levobunolol (l-Bunolol) is a non-selective β-adrenergic antagonist and vasodilator. By blocking calcium ion influx and reducing the sensitivity of vascular smooth muscle to calcium, Levobunolol effectively dilates the ciliary arteries and increases ocular blood flow, so it is widely used in research on glaucoma and ocular hypertension. Levobunolol inhibits the β-receptor signaling pathway and the expression of related proliferation markers (such as CK3, CK14, CK19, Ki67) in corneal cells. In rabbit models, Levobunolol not only does not inhibit corneal epithelial regeneration, but also accelerates the healing of mechanical injury without adverse effects. Levobunolol also inhibits histamine-induced vasoconstriction and intracellular calcium elevation, exhibiting unique vascular regulatory activity. Levobunolol protects ocular blood flow and promotes corneal repair .
    Levobunolol
  • HY-117991
    DW10075

    		VEGFR Cancer
    DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
    DW10075
  • HY-RS21649
    Mki67 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mki67 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mki67 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mki67 Mouse Pre-designed siRNA Set A
    Mki67 Mouse Pre-designed siRNA Set A
  • HY-181842
    PARP1/ERK IN-1

    		PARP ERK Apoptosis Cancer
    PARP1/ERK IN-1 is a dual PARP1/ERK inhibitor, with a PARP1 IC50 of 0.9 nM and an ERK2 IC50 of 1.8 nM. PARP1/ERK IN-1 inhibits proliferation and migration of various cancer cell lines, and induces apoptosis and DNA damage. PARP1/ERK IN-1 suppresses tumor growth in mouse models of colorectal cancer, and reduces the expression of Ki‑67, BRCA1 and Rad51. PARP1/ERK IN-1 can be used in the research of colorectal cancer, triple-negative breast cancer and pancreatic cancer .
    PARP1/ERK IN-1
  • HY-A0169AR
    Methyl aminolevulinate hydrochloride (Standard)

    		Reactive Oxygen Species (ROS) Reference Standards Photosensitizer Inflammation/Immunology Cancer
    Methyl aminolevulinate hydrochloride (Standard) is the analytical standard of Methyl aminolevulinate hydrochloride. This product is intended for research and analytical applications. Methyl aminolevulinate hydrochloride is a sensitizer used in photodynamic therapy (PDT). Methyl aminolevulinate hydrochloride penetrates the skin and induces the production of photoactive porphyrins including protoporphyrin IX in cells; upon exposure to appropriate light, it generates ROS, which triggers cellular oxidation and cell death. Methyl aminolevulinate hydrochloride acts as a photo-damage reversing agent through epidermal reconstruction, cytokine-mediated activation of dermal fibroblasts, elastin breakdown, new collagen formation, and compression of dilated capillaries. Methyl aminolevulinate hydrochloride reduces the expression of the proliferation marker Ki-67 and the early skin carcinogenesis marker TP53. Methyl aminolevulinate hydrochloride delays the onset of ultraviolet-induced skin tumors and reduces tumor burden in hairless mice. Methyl aminolevulinate hydrochloride is applicable to research related to actinic keratosis and basal cell carcinoma .
    Methyl aminolevulinate hydrochloride (Standard)
  • HY-183335
    SMO-IN-6

    		Smo Hedgehog Gli Apoptosis Caspase Cancer
    Anticancer agent 321 is a Smoothened (SMO) inhibitor with a human IC50 of 0.12 μM, enhanced aqueous solubility, good plasma and metabolic stability, moderate therapeutic index, preliminary safety profile, and moderate oral bioavailability in rats.Anticancer agent 321 binds to SMO’s 7-transmembrane helical channel, forming hydrogen bonds with Asp384 and hydrophobic/π-π interactions with His470, Phe391, Tyr394, stabilizing SMO’s inactive conformation to inhibit Hedgehog/GLI signaling.Anticancer agent 321 inhibits proliferation, suppresses colony formation, induces apoptosis, and downregulates Hedgehog/GLI pathway target genes GLI1, GLI2, Ptch1, HHip in cancer cells.Anticancer agent 321 inhibits tumor growth, downregulates Ki67 and SOX2, and upregulates cleaved-caspase 3 in tumor tissues.Anticancer agent 321 can be used for the research of cutaneous squamous cell carcinoma .
    SMO-IN-6
  • HY-181687
    Hsp90-IN-46

    		HSP CDK Cancer
    Hsp90-IN-46 is a Hsp90 inhibitor. Hsp90-IN-46 exhibits broad-spectrum antiproliferative activity against tumor cell lines. Hsp90-IN-46 inhibits breast cancer cell proliferation by reducing colony formation and downregulating the proliferation marker Ki-67. Hsp90-IN-46 inhibits Hsp90 and its ATPase activity, downregulates the downstream substrate oncoproteins HER2 and CDK4, and moderately induces the heat shock response. Hsp90-IN-46 shows significant antitumor activity in a mouse model of triple-negative breast cancer tumor xenografts. Hsp90-IN-46 can be used for research on various cancers including triple-negative breast cancer, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer .
    Hsp90-IN-46
  • HY-182470
    AG-012986 dihydrochloride

    		CDK
    AG-012986 (dihydrochloride) is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 (dihydrochloride) causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 (dihydrochloride) induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 (dihydrochloride) exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 (dihydrochloride) can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
    AG-012986 dihydrochloride
  • HY-183078
    P6620

    		Deubiquitinase Cancer
    P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma .
    P6620

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: